Leadership Overview
Gufic Group has 4 executives leading key functions including operations, finance, human resources, and sales.
Driven by a commitment to innovation, Gufic Group is dedicated to advancing pharmaceutical and herbal products, impacting healthcare across India and beyond.
Driven by a commitment to innovation, Gufic Group is dedicated to advancing pharmaceutical and herbal products, impacting healthcare across India and beyond.
Leadership Roles at Gufic Group
Devkinandan Roonghta - Chief Financial Officer
Devkinandan Roonghta, the Chief Financial Officer at Gufic Group, manages all financial aspects of the organization, providing strategic financial guidance. Overseeing financial planning and analysis, Devkinandan Roonghta ensures robust fiscal management for the company's diverse product lines, including APIs and lyophilized injections. This critical role involves managing capital allocation, optimizing investment strategies, and ensuring compliance with financial regulations across Gufic's operations. The Chief Financial Officer's responsibilities include driving profitability, managing risk, and supporting the company's growth objectives, particularly in expanding its international footprint. By maintaining strong financial discipline, Devkinandan Roonghta directly contributes to Gufic Group's sustained development and its ability to fund ongoing research and development for advanced new products.
Nagesh Yarrabathina - Chief Operating Officer
Nagesh Yarrabathina, the Chief Operating Officer at Gufic Group, directs the company's extensive operational activities, ensuring the efficient production and distribution of pharmaceutical and herbal products. Overseeing manufacturing processes, Nagesh Yarrabathina guarantees adherence to stringent quality standards for antibiotics, antifungals, and antiviral treatments. This leadership role involves managing the supply chain for lyophilized injections, a key area of Gufic's expertise, and coordinating logistics to major hospital chains across India. The Chief Operating Officer's focus extends to optimizing production workflows and driving operational excellence to support the company's research and development initiatives and international expansion. By streamlining operations, the Chief Operating Officer ensures Gufic Group maintains its position as a leading pharmaceutical manufacturer.
Shekhar Aley - President, Sales & Marketing-Critical Care Sbus Indianepalinneurocare
Shekhar Aley, the President, Sales & Marketing-Critical Care Sbus Indianepalinneurocare at Gufic Group, drives the strategic direction for sales and marketing initiatives across critical care, Indian, Nepali, and neurocare business units. Overseeing market penetration and revenue generation, Shekhar Aley ensures Gufic Group's pharmaceutical and herbal products reach key hospital chains and medical facilities. This executive role involves developing and executing comprehensive sales strategies, managing marketing campaigns, and expanding the company's market share within India and internationally. The President, Sales & Marketing's focus is on strengthening Gufic's brand presence and driving demand for its diverse product portfolio, including antibiotics, antifungals, and antiviral treatments. By leading these commercial efforts, Shekhar Aley directly supports the company's commitment to research and development and its objective of continuous product innovation.
Sunil Desai - Chief Human Resources Officer
Sunil Desai, the Chief Human Resources Officer at Gufic Group, leads all human capital strategies, fostering a productive and innovative work environment. Overseeing talent acquisition and development, Sunil Desai ensures Gufic Group attracts and retains skilled professionals essential for pharmaceutical and herbal product innovation. This leadership position involves shaping organizational culture, managing employee relations, and implementing HR policies that support the company's mission and growth. The Chief Human Resources Officer plays a vital part in aligning human resources with Gufic's strategic objectives, including its expansion into international markets and its commitment to research and development. By cultivating a strong workforce, Sunil Desai directly supports the company's capacity to produce high-quality products and maintain its leadership in lyophilized injection manufacturing.
Explore Leadership Teams in Manufacturing
AstraZeneca focuses on the discovery, development, and commercialization of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. AstraZeneca is based in the United Kingdom.
Company Leadership KO
JZ
Renata Limited is a pharmaceutical and animal health product manufacturing company headquartered in Dhaka, Bangladesh. Their products include a variety of human pharmaceuticals, including synthetic hormones, oncological drugs, contraceptives, and more, as well as animal health and nutrition products. The company was founded in 1972 as Pfizer Bangladesh and changed ownership and name to Renata Limited in 1993.
Company Leadership NA
MA
Morepen Laboratories is a leading pharmaceutical company specializing in Active Pharmaceutical Ingredients (APIs) and finished formulations. With a commitment to quality and innovation, the company offers a wide range of healthcare, grooming, and OTC products under trusted brands like Dr. Morepen and Gubb World, catering to over 100 million consumers. Morepen has a robust global presence, exporting to over 80 countries and holding certifications from regulatory authorities such as USFDA and WHO GMP. The company is dedicated to enhancing lives through its extensive research and development efforts and state-of-the-art manufacturing facilities.
Company Leadership TA
KS
PM
ImmunityBio is a vertically-integrated biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The Companys range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates natural killer cells, T cells, and memory T cells for a long-duration response. The Company is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases.
Company Leadership FJ
Frequently Asked Questions Regarding Gufic Group Top Executives and Leadership Team
